#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	5898	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2577	509.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1566	1566	C	763	C,G,A,T	591,3,2,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	5898	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2577	509.3	0	HET	.	.	.	C207T,G	.	207	207	C	589	589	C	581	C,T,G	264,186,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	10408	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3985	575.7	0	.	n	.	0	T695C	SNP	695	695	T	1170	1170	C	696	C,A,G,T	506,4,3,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	10408	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3985	575.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	1812	1812	A	651	A,G,C	534,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	10408	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3985	575.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2446	2446	C	734	C,G	571,4	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	10408	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3985	575.7	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3072	3072	T	784	T,G,A	618,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	10408	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3985	575.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2520	2520	A	707	A	547	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	862	folP	852	852	100.0	folP.l15.c4.ctg.1	1990	98.3	1	SNP	p	R228S	1	.	.	682	684	AGC	1271	1273	AGC	147;147;148	A,G;G;C,A	120,1;121;120,1	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1840	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3898	106.3	1	SNP	p	S91F	0	.	.	271	273	TCC	849	851	TCC	122;122;122	T;C;C	86;89;91	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1840	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3898	106.3	1	SNP	p	D95N	0	.	.	283	285	GAC	861	863	GAC	133;134;134	G,C;A;C,A,T	101,1;98;99,3,1	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1840	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3898	106.3	1	SNP	p	D95G	0	.	.	283	285	GAC	861	863	GAC	133;134;134	G,C;A;C,A,T	101,1;98;99,3,1	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	408	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1323	67.4	0	.	p	.	0	A39T	NONSYN	115	117	GCC	489	491	ACC	110;114;113	A;C;C	81;86;85	.	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	408	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1323	67.4	0	.	p	.	0	R44H	NONSYN	130	132	CGC	504	506	CAC	113;111;111	C;A;C	80;82;80	.	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	408	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1323	67.4	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	687	689	CAC	114;112;111	C,A;A,C;C,T,A	88,1;85,3;83,1,1	.	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	408	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1323	67.4	1	SNP	p	G45D	0	.	.	133	135	GGC	507	509	GGC	111;112;112	G;G;C	78;79;79	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	362	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1359	58.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1984	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3208	139.0	1	SNP	p	D86N	0	.	.	256	258	GAC	686	688	GAC	143;142;144	G,C;A,C;C	102,1;77,1;93	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1984	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3208	139.0	1	SNP	p	S87I	0	.	.	259	261	AGT	689	691	AGT	145;148;155	A;G;T,G	90;101;116,2	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1984	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3208	139.0	1	SNP	p	S87W	0	.	.	259	261	AGT	689	691	AGT	145;148;155	A;G;T,G	90;101;116,2	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1984	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3208	139.0	1	SNP	p	S87R	0	.	.	259	261	AGT	689	691	AGT	145;148;155	A;G;T,G	90;101;116,2	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1984	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3208	139.0	1	SNP	p	S88P	0	.	.	262	264	TCC	692	694	TCC	154;155;155	T;C,T,G;C	117;119,1,1;122	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1876	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3253	132.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1897	1899	GGC	139;140;140	G,A;G;C	108,1;108;105	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	1510	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2309	141.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1307	1309	GCA	242;246;247	G,T;C,A;A	184,1;189,1;194	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1510	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2309	141.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1310	1312	ATC	247;247;246	A,G;T,G;C,G	190,1;196,1;196,1	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1510	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2309	141.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1322	1324	GTG	243;244;245	G;T;G,A	191;195;197,1	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1510	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2309	141.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1322	1324	GTG	243;244;245	G;T;G,A	191;195;197,1	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1510	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2309	141.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1826	1828	ACC	165;165;165	A,C,G;C;C,A	113,1,1;120;122,1	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1510	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2309	141.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1880	1882	GCG	126;122;122	G,A;C;G	100,1;89;97	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1510	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2309	141.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1880	1882	GCG	126;122;122	G,A;C;G	100,1;89;97	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1510	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2309	141.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2003	2005	GGC	99;99;99	G,T;G;C,T,G	82,1;84;79,3,2	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1510	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2309	141.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2012	2014	GGC	93;93;90	G,A;G;C,A	74,1;72;63,1	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1510	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2309	141.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2030	2032	CCG	86;86;85	C;C,G;G,T	61;56,2;61,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1852	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3557	111.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	658	porA	1146	1146	99.83	porA.l6.c30.ctg.1	1803	77.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	463	463	C	57	C,G	39,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	730	porB1b	1035	1035	95.73	porB1b.l15.c30.ctg.1	1518	101.7	0	.	p	.	0	G50D	NONSYN	148	150	GGC	315	317	GAC	124;124;124	G;A;C,A	90;90;90,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	730	porB1b	1035	1035	95.73	porB1b.l15.c30.ctg.1	1518	101.7	0	.	p	.	0	F135L	NONSYN	403	405	TTT	570	572	CTT	128;130;130	C;T;T,C,A	100;100;100,1,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	730	porB1b	1035	1035	95.73	porB1b.l15.c30.ctg.1	1518	101.7	0	.	p	.	0	R143G	NONSYN	427	429	AGA	594	596	GGA	138;140;140	G;G;A	106;107;104	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	730	porB1b	1035	1035	95.73	porB1b.l15.c30.ctg.1	1518	101.7	0	.	p	.	0	D171G	NONSYN	511	513	GAT	678	680	GGT	148;147;144	G;G,C,T;T,A,G,C	114;111,1,1;106,2,1,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	730	porB1b	1035	1035	95.73	porB1b.l15.c30.ctg.1	1518	101.7	0	.	p	.	0	G189S	NONSYN	565	567	GGC	732	734	AGC	153;153;149	A,G;G,T;C,T	106,1;108,1;104,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	730	porB1b	1035	1035	95.73	porB1b.l15.c30.ctg.1	1518	101.7	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	798	798	T	147	T	104	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	730	porB1b	1035	1035	95.73	porB1b.l15.c30.ctg.1	1518	101.7	1	SNP	p	G120K	0	.	.	358	360	GGT	525	527	GGT	122;122;122	G;G;T	91;94;92	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	730	porB1b	1035	1035	95.73	porB1b.l15.c30.ctg.1	1518	101.7	1	SNP	p	A121N	0	.	.	361	363	GCC	528	530	GCC	124;123;121	G,A;C;C	93,1;93;92	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	730	porB1b	1035	1035	95.73	porB1b.l15.c30.ctg.1	1518	101.7	1	SNP	p	A121D	0	.	.	361	363	GCC	528	530	GCC	124;123;121	G,A;C;C	93,1;93;92	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	3542	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4841	160.6	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1769	1771	AAT	177;179;179	A;A;T	143;144;142	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	248	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1216	47.1	1	SNP	p	V57M	1	.	.	169	171	ATG	696	698	ATG	90;89;90	A;T;G	69;68;69	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
